Indian pharma firm expected to produce 100 million doses of Sputnik V vaccine next year

The pharma firm through its subsidiary Hetero Biopharma intends to start the production of Sputnik V in the beginning of 2021. Russia Direct Investment Fund on November 27 announced their agreement with Hyderabad-based drug maker Hetero Biologics, to produce over 100 million doses of Russia's Covid-19 vaccine Sputnik V in India. The Healthworld. asiaplustj.info »